OGN - Merck Stock Still Looks Attractive Despite Pfizer Competition
- Merck fell almost 10% on Friday after Pfizer announced its own antiviral pill.
- The stock is now up less than 10% after its pre-antiviral announcement levels, offering an attractive entry point.
- Merck could earn upwards to $1 per share in incremental EPS from its molnupiravir Covid treatment.
- The risk reward appears very favorable even without meaningful earnings from molnupiravir.
- Indeed, excluding any future earnings from the antiviral, and MRK is trading at a bargain 12.6x earnings, below long-term averages still.
For further details see:
Merck Stock Still Looks Attractive Despite Pfizer Competition